FRAZIER KENNETH C

SEC Form 4 insider trading activity

FRAZIER KENNETH C has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 6, 2026.

On the most recent filing, FRAZIER KENNETH C is listed as Director at Eikon Therapeutics, Inc. Inside the rolling window, FRAZIER KENNETH C reported 1 open-market purchase totaling $2.0M in EIKN and no open-market sales.

Companies traded

Other insiders at EIKN

Insider Buying

$2.0M

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
EIKN
FRAZIER KENNETH C
Purchase$2.0MFeb 6SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has FRAZIER KENNETH C made?

FRAZIER KENNETH C has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does FRAZIER KENNETH C trade?

FRAZIER KENNETH C has filed SEC Form 4 disclosures for 1 company, including EIKN.

When was FRAZIER KENNETH C's most recent SEC Form 4 filing?

FRAZIER KENNETH C's most recent SEC Form 4 filing on Tracefour is dated Feb 6, 2026.

What is FRAZIER KENNETH C's total buy and sell value in the current window?

Inside the rolling retention window, FRAZIER KENNETH C bought $2.0M and sold $0 based on SEC Form 4 filings.

What was FRAZIER KENNETH C's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 111,111 EIKN shares on 2026-02-04, worth $2.0M, per SEC Form 4 filings.